PL1720611T3 - Marker diagnostyczny dla raka - Google Patents
Marker diagnostyczny dla rakaInfo
- Publication number
- PL1720611T3 PL1720611T3 PL05707434T PL05707434T PL1720611T3 PL 1720611 T3 PL1720611 T3 PL 1720611T3 PL 05707434 T PL05707434 T PL 05707434T PL 05707434 T PL05707434 T PL 05707434T PL 1720611 T3 PL1720611 T3 PL 1720611T3
- Authority
- PL
- Poland
- Prior art keywords
- cancer
- diagnostic marker
- marker
- diagnostic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Pathology (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- General Engineering & Computer Science (AREA)
- Hospice & Palliative Care (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102004008449 | 2004-02-16 | ||
DE102004038076A DE102004038076A1 (de) | 2004-02-16 | 2004-07-29 | Diagnostische Marker für Krebs |
PCT/EP2005/001567 WO2005078124A2 (de) | 2004-02-16 | 2005-02-16 | Diagnostische marker für krebs |
EP05707434A EP1720611B1 (de) | 2004-02-16 | 2005-02-16 | Diagnostische marker für krebs |
Publications (1)
Publication Number | Publication Date |
---|---|
PL1720611T3 true PL1720611T3 (pl) | 2010-09-30 |
Family
ID=34862916
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL05707434T PL1720611T3 (pl) | 2004-02-16 | 2005-02-16 | Marker diagnostyczny dla raka |
Country Status (7)
Country | Link |
---|---|
US (1) | US20070172900A1 (pl) |
EP (1) | EP1720611B1 (pl) |
JP (1) | JP5068543B2 (pl) |
AU (1) | AU2005212829B2 (pl) |
CA (1) | CA2555866A1 (pl) |
PL (1) | PL1720611T3 (pl) |
WO (1) | WO2005078124A2 (pl) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20080046750A (ko) * | 2000-03-24 | 2008-05-27 | 바이오스피어 메디칼 인코포레이티드 | 능동 색전화용 미소구 |
US20100266495A1 (en) * | 2004-05-21 | 2010-10-21 | Brigham Young University | Anti-Cancer Activity of an Anti-Thymidine Kinase Monoclonal Antibody |
EP3085362B1 (en) | 2005-05-09 | 2021-01-13 | Biosphere Medical, S.A. | Compositions and methods using microspheres and non-ionic contrast agents |
EP1724585A1 (en) | 2005-05-21 | 2006-11-22 | ProteoSys AG | Annexin for cancer risk assessment |
EP1724586A3 (en) | 2005-05-21 | 2007-07-04 | ProteoSys AG | Annexin for cancer risk assessment |
EP1991274A4 (en) * | 2006-01-20 | 2009-06-10 | Women S And Children S Health | METHOD FOR THE TREATMENT, PROPHYLAXIS AND DIAGNOSIS OF BONE DISEASES |
CA2644855C (en) * | 2006-03-09 | 2019-11-19 | Aethlon Medical, Inc. | Extracorporeal removal of microvesicular particles |
WO2007141043A2 (en) | 2006-06-09 | 2007-12-13 | Proteosys Ag | Monoclonal anti-annexin a3 antibodies for the detection of prostate carcinoma |
CN100571785C (zh) * | 2006-09-06 | 2009-12-23 | 中国医学科学院北京协和医院 | Annexin A3与癌症的铂类化疗药物耐药性的相关性 |
KR100815292B1 (ko) | 2007-01-17 | 2008-03-19 | 인제대학교 산학협력단 | 위암 진단 마커로서의 미토콘드리아 에노일 조효소 a히드라타아제 1 |
US20100255514A1 (en) | 2007-08-16 | 2010-10-07 | The Royal Institution For The Advancement Of Learning/Mcgill University | Tumor cell-derived microvesicles |
EP2696203A3 (en) * | 2007-08-16 | 2014-05-28 | The Royal Institution for the Advancement of Learning/McGill University | Tumor cell-derived microvesicles |
GR1006121B (el) | 2007-10-26 | 2008-10-24 | ��������������� ������� ��������� ������ (40%) | Η πρωτεϊνη serum amyloid p-component (sap,samp) ως προγνωστικος και διαγνωστικος δεικτης για τον προγεννητικο ελεγχο της τρισωμιας 21 (συνδρομο down) |
WO2010062706A2 (en) * | 2008-10-30 | 2010-06-03 | Caris Mpi, Inc. | Methods for assessing rna patterns |
EP2350320A4 (en) | 2008-11-12 | 2012-11-14 | Caris Life Sciences Luxembourg Holdings | METHODS AND SYSTEMS FOR USING EXOSOMES TO DETERMINE PHENOTYPES |
WO2010065968A1 (en) * | 2008-12-05 | 2010-06-10 | Myriad Genetics, Inc. | Cancer detection markers |
GB0822836D0 (en) * | 2008-12-15 | 2009-01-21 | Oxford Biomedica Ltd | Method |
EP2320234A1 (en) | 2009-11-06 | 2011-05-11 | IMG Institut für medizinische Genomforschung Planungsgesellschaft M.B.H. | Marker combination for prostate cancer diagnosis |
EP2320235A1 (en) * | 2009-11-06 | 2011-05-11 | IMG Institut für medizinische Genomforschung Planungsgesellschaft M.B.H. | Marker for prostate cancer diagnosis |
WO2011082345A2 (en) * | 2009-12-30 | 2011-07-07 | Brigham Young University | Compositions and methods for cancer management using antibodies binding to nucleotide salvage pathway enzymes and complexes thereof |
CA2791905A1 (en) | 2010-03-01 | 2011-09-09 | Caris Life Sciences Luxembourg Holdings, S.A.R.L. | Biomarkers for theranostics |
KR20130043104A (ko) | 2010-04-06 | 2013-04-29 | 카리스 라이프 사이언스 룩셈부르크 홀딩스 | 질병용 순환 생물학적 지표들 |
JP2011226882A (ja) * | 2010-04-19 | 2011-11-10 | Kitasato Institute | 泌尿器系疾患マーカー及びその抗体、並びに泌尿器系疾患診断用キット |
CA2827894A1 (en) * | 2011-02-22 | 2012-08-30 | Caris Life Sciences Luxembourg Holdings, S.A.R.L. | Circulating biomarkers |
WO2013076222A1 (en) | 2011-11-23 | 2013-05-30 | Proteosys Ag | Differential annexin a3 measurements of serum and blood derivatives or fractions thereof for the diagnosis of prostate cancer |
US20150140013A1 (en) * | 2012-09-21 | 2015-05-21 | The General Hospital Corporation | Modulation of asymmetric proliferation |
US9903870B2 (en) | 2012-10-04 | 2018-02-27 | The Wistar Institute Of Anatomy And Biology | Methods and compositions for the diagnosis of ovarian cancer |
KR102065112B1 (ko) * | 2013-02-28 | 2020-01-10 | 삼성전자주식회사 | 높은 항원 선택성을 갖는 항체의 스크리닝 방법 |
TWI788704B (zh) | 2013-10-24 | 2023-01-01 | 美商納諾索米克斯公司 | 分析個體樣品之方法 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6476207B1 (en) * | 1998-06-11 | 2002-11-05 | Chiron Corporation | Genes and gene expression products that are differentially regulated in prostate cancer |
US6486207B2 (en) * | 1998-12-10 | 2002-11-26 | Nexmed (Holdings), Inc. | Compositions and methods for amelioration of human female sexual dysfunction |
US6645465B2 (en) * | 1999-08-06 | 2003-11-11 | Michigan, University Of The Regents | Annexin proteins and autoantibodies as serum markers for cancer |
GB0000993D0 (en) * | 2000-01-18 | 2000-03-08 | Univ Nottingham Trent | Cancer associated genes and their products |
EP1272617B1 (en) * | 2000-04-01 | 2011-04-27 | Onyvax Limited | Prostate cell lines and their use |
US6673545B2 (en) * | 2000-07-28 | 2004-01-06 | Incyte Corporation | Prostate cancer markers |
KR20030061384A (ko) * | 2000-11-01 | 2003-07-18 | 가르파마 컴퍼니 리미티드 | 암 전이능 검출제 |
PL363009A1 (pl) * | 2001-04-03 | 2004-11-15 | Merck Patent Gmbh | Markery nowotworowe raka nerki |
US20030108963A1 (en) * | 2001-07-25 | 2003-06-12 | Millennium Pharmaceuticals, Inc. | Novel genes, compositions, kit, and methods for identification, assessment, prevention and therapy of prostate cancer |
US7229774B2 (en) * | 2001-08-02 | 2007-06-12 | Regents Of The University Of Michigan | Expression profile of prostate cancer |
JP2004135667A (ja) * | 2002-09-27 | 2004-05-13 | Japan Science & Technology Agency | 血液を用いた統合失調症の診断方法 |
-
2005
- 2005-02-16 CA CA002555866A patent/CA2555866A1/en not_active Abandoned
- 2005-02-16 PL PL05707434T patent/PL1720611T3/pl unknown
- 2005-02-16 AU AU2005212829A patent/AU2005212829B2/en not_active Ceased
- 2005-02-16 JP JP2006553527A patent/JP5068543B2/ja not_active Expired - Fee Related
- 2005-02-16 EP EP05707434A patent/EP1720611B1/de active Active
- 2005-02-16 US US10/589,487 patent/US20070172900A1/en not_active Abandoned
- 2005-02-16 WO PCT/EP2005/001567 patent/WO2005078124A2/de active Application Filing
Also Published As
Publication number | Publication date |
---|---|
WO2005078124A3 (de) | 2006-08-10 |
JP5068543B2 (ja) | 2012-11-07 |
AU2005212829A1 (en) | 2005-08-25 |
CA2555866A1 (en) | 2005-08-25 |
AU2005212829B2 (en) | 2010-09-09 |
US20070172900A1 (en) | 2007-07-26 |
EP1720611A2 (de) | 2006-11-15 |
WO2005078124A2 (de) | 2005-08-25 |
EP1720611B1 (de) | 2010-05-19 |
JP2007527001A (ja) | 2007-09-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PL1720611T3 (pl) | Marker diagnostyczny dla raka | |
EP1797903A4 (en) | DIAGNOSTIC AGENT FOR TUMOR | |
IL227562A (en) | Symptoms of breast cancer | |
AP2006003862A0 (en) | Oligonucleotides for cancer diagnosis | |
IL190882A0 (en) | Compositions for cancer therapy | |
EP1967209A4 (en) | THERAPEUTIC AGENT AGAINST PROSTATE CANCER | |
EP2079385A4 (en) | MAMMARY MARKER | |
EP1747284A4 (en) | DIAGNOSTICS AND THERAPEUTICS OF CANCER | |
EP1802764A4 (en) | BIOLOGICAL MARKERS FOR BREAST CANCER | |
PT1830847E (pt) | Tratamento para o cancro | |
GB0421838D0 (en) | Cancer markers | |
AU304007S (en) | Dress-making line marker | |
HK1110224A1 (en) | Therapeutic agent for cancer | |
EP1966607A4 (en) | MAC-2 BINDING PROTEIN AS A MARKER IN THE DIAGNOSIS OF GASTRIC CANCER | |
GB0401876D0 (en) | New use for cancer antigen | |
EP2092884A4 (en) | MEDICAL IMAGING MARKER | |
EP1987846A4 (en) | DIAGNOSTIC MARKER | |
GB2421692B (en) | Distance marker | |
GB0525900D0 (en) | Markers | |
EP1876447A4 (en) | MEANS OF TUMOR DIAGNOSIS | |
GB0522112D0 (en) | Novel imaging agents for cancer | |
GB0500862D0 (en) | Line marker | |
GB0413204D0 (en) | Marker | |
IL192875A0 (en) | Marker and method for cancer diagnosis | |
GB0427691D0 (en) | Markers for inf- response |